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of obesity is not the result of decreased
endogenous leptin action.
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Obesity is characterized by hyperleptinemia and
decreased response to exogenous leptin. This has
been widely attributed to the development of leptin
resistance, a state of impaired leptin signaling pro-
posed to contribute to the development and persis-
tence of obesity. To directly determine endogenous
leptin activity in obesity, we treated lean and obese
mice with a leptin receptor antagonist. The antago-
nist increased feeding and body weight (BW) in
leanmice, but not in obesemodels of leptin, leptin re-
ceptor, or melanocortin-4 receptor deficiency. In
contrast, the antagonist increased feeding and BW
comparably in lean and diet-induced obese (DIO)
mice, an increase associated with decreased hypo-
thalamic expression of Socs3, a primary target of
leptin. These findings demonstrate that hyperleptine-
mic DIO mice retain leptin suppression of feeding
comparable to lean mice and counter the view that
resistance to endogenous leptin contributes to the
persistence of DIO in mice.
INTRODUCTION
Leptin is a 16 kDa hormone secreted by adipocytes (Zhang
et al., 1994) that plays a critical role in the control of feeding
by acting on specific neurons in the CNS (Myers et al., 2008).
Individuals lacking circulating leptin are hyperphagic and
obese, features that can be reversed with administration of
exogenous leptin (Halaas et al., 1995). In contrast, more com-
mon forms of obesity, including diet-induced obesity (DIO),
exhibit hyperleptinemia proportional to the amount of body
fat stores (Frederich et al., 1995). The inability of high endoge-
nous leptin levels to reduce feeding and mitigate or reverse
weight gain is referred to as leptin resistance, and it has been
implicitly associated with the impairment of leptin action (Myers
et al., 2012). Consistent with this thesis, obese hyperleptinemic
animals have a blunted anorectic response to exogenously
administered leptin and an associated attenuation of the leptin
receptor (LEPR)-dependent intracellular signaling cascade
(Enriori et al., 2007).CWhile the resistance of obese subjects to exogenous leptin
has been widely documented, the action of endogenous leptin
to control energy balance in obesity has not been rigorously
tested. We hypothesized that blockade of the LEPR in mouse
models of obesity would give an estimate of endogenous leptin
action reflected in changes in food intake andBW. This approach
was taken with genetic and diet-induced models of obese mice.
Our results demonstrate that despite the presence of hyperlep-
tinemia, wild-type (WT) DIO mice retain a degree of endogenous
leptin action similar to that of their lean counterparts. Thus, per-
sistance of obesity in DIO mice occurs despite ongoing endoge-
nous leptin action.RESULTS
Intraperitoneal PLA Increases Food Intake and Body
Weight in Wild-Type Mice, but Not in Mice with Impaired
Leptin Signaling
We assessed the in vivo specificity of a pegylated leptin receptor
antagonist (PLA) by comparing the effect of daily administration
(3 mg/kg intraperitoneal [i.p.], daily) on energy intake and BW
in leptin receptor-deficient (leprdbdb, db/db), leptin-deficient
(lepobob, ob/ob), and age-matched WT control mice over
1 week (Figure 1). Untreated db/db and ob/ob mice had signifi-
cant hyperphagia compared to untreatedWTcontrols (Figure 1A,
see also Figure S1A). Consistent with a blockade of endogenous
leptin action, PLA significantly increased 1 week energy intake in
WTmice. In contrast, PLA failed to increase feeding in ob/ob or in
db/db mice (Figure 1A). PLA significantly increased BW (Fig-
ure 1B) and BW gain (Figure 1C) in lean WT control mice
compared to vehicle-treated controls, but failed to affect BW in
db/db mice. Interestingly, there was a small but significant
reduction in BW gain in ob/obmice treated with PLA (Figure 1C).Intraperitoneal PLA or Intracerebroventricular LA
Increases Food Intake and Body Weight in WT Mice, but
Not in Obese Melanocortin 4-Receptor-Deficient Mice
Themelanocortin system plays a critical role mediating the effect
of leptin on food intake and BW (Seeley et al., 1997). Mice with a
homozygous deletion of MC4R (Mc4r/ mice) are hyperphagic
and develop obesity in adulthood that is associated with hyper-
leptinemia and reduced effectiveness of exogenous leptin
(Marsh et al., 1999). To investigate the contribution of MC4R to
the actions of endogenous leptin, obese Mc4r/ mice and WTell Metabolism 21, 877–882, June 2, 2015 ª2015 Elsevier Inc. 877
A B C Figure 1. Peripheral Administration of PLA,
3 mg/kg i.p. Once Daily, in Chow-Fed db/
db, ob/ob, or Lean WT Control Mice
(A–C) Daily injection of PLA increases energy
intake (A), BW (B), and BW change (C) in lean
chow-fed control mice, but not in mice voided of
endogenous leptin signaling. Data are shown as
mean ± SEM, n = 6. *p < 0.05 WT Veh versus WT
PLA; #p < 0.05 ob/ob Veh versus ob/ob PLA. Two-
way repeated-measures (RM) ANOVA followed by
Sidak test.littermates received peripheral PLA (3 mg/kg/day, i.p.) for
1 week. PLA significantly increased energy intake in WT (p <
0.05 treatment 3 time), but not in obese Mc4r/, mice (Fig-
ure 2A, see also Figure S1B). 1 week PLA treatment did not affect
total BW (Figure 2B) but promoted a significant BWchange inWT
mice relative to vehicle-treated controls (Figure 2C). In contrast,
leptin receptor blockade did not change BW in obese Mc4r/
mice (Figure 2C). PLA was dosed based on BW (1.65-fold differ-
ence), but plasma leptin levels were 9.5-fold higher in obese
Mc4r/ in comparison to their WT controls (41.34 ± 2.11 versus
4.35 ± 2.46 ng/ml, p < 0.05), raising the possibility of insufficient
antagonism to counteract the higher levels of endogenous leptin.
To ensuremaximal reduction of endogenous leptin action, obese
Mc4r/ mice and lean WT littermates received an infusion of
non-pegylated antagonist (LA, 8 mg/day) for 1 week directly
into the lateral cerebral ventricle (intracerebroventricular, i.c.v.)
using osmotic minipumps. LA induced significant hyperphagia
(Figure 2D, see also Figure S1C) and BW gain (Figures 2E and
2F) in lean WT, but not in obese Mc4r/ mice, despite a trend
toward a BW change in the latter (p = 0.059, Figure 2F). Since
young, preobeseMc4r/mice retain responsiveness to exoge-
nous leptin (Marsh et al., 1999), we treated a cohort of younger
Mc4r/ (28.5 ± 1.5 g) and age-matched WT littermates (24.1 ±
1.0 g) with PLA (3 mg/kg/day, i.p.) for 1 week. PLA did not affect
total BW (Figure S1D) but increased the BW gain relative to
vehicle-treated controls, as well as energy intake, in Mc4r/
mice (p < 0.05 treatment 3 time; Figures S1E and S1F) and in
their WT littermates (Figures S1E–S1G).
Intraperitoneal PLA or Intracerebroventricular LA
Increases Food Intake and BW in Lean and DIO Mice
DIOmice are frequently used as amodel of leptin resistance. DIO
mice and age-matched, chow-fed lean controls were treated
with PLA (1, 3, or 10 mg/kg i.p. once daily) for 7 days (lower
doses) or 6 days (highest dose). PLA at 1 mg/kg/day significantly
increased energy intake in lean mice only (Figure 3A, see also
Figure S1H) and did not change BW in lean or DIO mice (Figures
3B and 3C). PLA at 3 mg/kg/day significantly increased food
intake (Figure 3B, see also Figure S1I) and total BW (Figure 3E,
p < 0.05 at day 7) in lean, but not in DIO, mice. However, both
lean and DIO mice treated with this dose of PLA exhibited signif-
icant BW change when compared to their vehicle controls (Fig-
ure 3F), despite a 10-fold increase in circulating leptin in DIO
mice compared to lean controls (29.60 ± 2.36 versus 2.94 ±
0.45 ng/ml, p < 0.05). PLA at 10 mg/kg/day significantly
increased energy intake (Figure 3G, see also Figure S1J) and
BW (Figures 3H and 3I) in both lean and DIO mice. To examine878 Cell Metabolism 21, 877–882, June 2, 2015 ª2015 Elsevier Inc.near-maximal effects of reducing endogenous leptin action, we
infused LA (8 mg/day) i.c.v. into lean and DIO mice for 7 days us-
ing osmotic minipumps. Intracerebroventricular LA significantly
increased food intake (Figure 3J, see also Figure S1K) in both
lean and DIOmice. LA also caused significant differences in total
BW (Figure 3K) and relative BW change (Figure 3L) compared to
vehicle-treated controls.
When the dose responses of PLA on energy intake and BW
change were compared, the effect of endogenous leptin to
restrain energy intake was comparable between lean and DIO
mice, with the exception of the dose of 3 mg/kg/day (Figure 3M),
whereas the BW change compared to vehicle-treated controls
were similar in lean and DIO mice with all doses (Figure 3N).
Effect of Reduction of Endogenous Leptin Action on
Pomc, Socs3, and Phosphorylated STAT3 Levels in the
Arcuate Nucleus of DIO Mice
Expression of two leptin-regulated genes, proopiomelanocortin
(Pomc) and suppressor of cytokine signaling-3 (Socs3), was
analyzed in the hypothalamic arcuate nucleus (ARC) following
acute or chronic PLA. DIO mice (BW 58.8 ± 1.2 g) received a sin-
gle dose of PLA (3 mg/kg i.p.) 1 hr prior to the onset of dark. The
mice had free access to water and HFD overnight and were
euthanized 1 hr after the onset of light. Food intake did not differ
during the experimental period (Figure S2A), but PLA-treated
mice exhibited a significant BW change in comparison to
vehicle-treated controls (Figure S2B), consistent with a reduction
in endogenous leptin signaling. Overnight PLA treatment did not
affect Pomc (Figure 4A) but significantly reduced Socs3 (Fig-
ure 4B) expression in the ARC of DIO mice.
Chronic PLA treatment (3 mg/kg i.p. daily for 7 days; Figures
3D–3F) significantly reduced both Pomc (Figure 4C) and Socs3
(Figure 4D) gene expression in lean and DIO mice. Pomc gene
expression was similar between lean and DIO mice treated
with vehicle (Figure 4C). In contrast, Socs3 expression was
significantly increased in vehicle-treated DIO mice in compari-
son to vehicle-treated lean controls (Figure 4D).
Levels of phosphorylated signal transducer and activator of
transcription-3 (pSTAT3) were analyzed by immunoblot (Fig-
ure S3) in the ARC of lean and DIO mice receiving i.c.v. LA
(8 mg/day) for 7 days (Figures S2C–S2F). Vehicle-treated DIO
mice had increased pSTAT3 in comparison to vehicle-treated
lean controls when normalized to beta actin content (Figure 4E).
Intracerebroventricular LA significantly reduced pSTAT3 in DIO
mice (Figure 4E), and pSTAT3 normalized to total STAT3 content
supported this finding (p = 0.061, DIO vehicle [Veh] versus DIO
LA; Figure 4F).
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Figure 2. Peripheral Administration of PLA
or Central Infusion of LA inChow-FedObese
Mc4r–/– or WT Littermate Control Male Mice
(A–F) Cumulative energy intake (A and D), BW
(B and E), and BW change (C and F) of obese
Mc4r/ mice and WT controls receiving either
peripheral PLA (3 nmol/kg/day i.p.) (A–C) or central
infusion of LA (8 mg/day, i.c.v.) (D–F) for 1 week.
Data are shown as mean ± SEM; n = 5–8. *p < 0.05
Mc4r+/+ Veh versus Mc4r+/+-treated mice. Two-
way RM ANOVA followed by Sidak test.DISCUSSION
In this study, central or peripheral treatment with a LEPR antag-
onist (D23L/L39A/D40A/F41A mutant) demonstrates a signifi-
cant role of endogenous leptin action regulating energy balance.
More importantly, our experiments consistently show compara-
ble contribution to the control of BW and suppression of food
intake by endogenous leptin in lean and hyperleptinemic DIO
mice, regardless of dose and route of administration. These find-
ings in a standard animal model of obesity often cited as leptin
resistant indicate that the current view on the role of leptin action
in obesity needs revision.
Consistent with our data, peripheral infusion of a different pe-
gylated antagonist (L39A/D40A/F41A mutant) increased feeding
in chow-fed mice (Levi et al., 2011). In contrast, central infusion
of the non-pegylated L39A/D40A/F41A antagonist failed to in-
crease feeding in chow-fed rats (Tu¨mer et al., 2007). In addition
to potential species-specific differences, this discrepancy with
our results is likely accounted for by the increased potency of
the antagonist used in our experiments, with greater binding to
leptin receptor (60-fold) and higher antagonistic activity (14-
fold) compared to the L39A/D40A/F41A mutant (Shpilman
et al., 2011). This increased potency, combined with the
extended duration of action provided by the addition of a poly-
ethylene glycol moiety, provides effectiveness to PLA when
admistered peripherally, results that are consistent with earlier
reports (Chapnik et al., 2013; Shpilman et al., 2011; Solomon
et al., 2014). Despite this increase in potency, PLA lacks orexi-
genic activity when given to db/db and ob/ob mice, which con-
firms its selectivity in vivo. Indeed, PLA reduces BW gain in ob/
ob mice, which could be the result of weak agonist activity,
considering that cytokine receptors such as the LEPR lack
intrinsic activity, and their signaling depends on the status of
associated kinases (Ishida-Takahashi et al., 2006).
A potential factor previously suggested as contributing to lep-
tin resistance in obesity is the impairment of the transport of lep-
tin through the blood-brain barrier (BBB) into the CNS (Banks
et al., 1999; Caro et al., 1996). To circumvent any role of differ-
ences in BBB permeability between lean and obese mice, weCell Metabolism 21, 877–compared peripheral and i.c.v. adminis-
tration of high doses of LEPR antagonist.
The observation that both lean and DIO
mice had comparable increases in energy
intake and BW that were proportional to
the doses of antagonist administered
peripherally or centrally demonstratesthat both groups experienced substantial restraint of food intake
by endogenous leptin, irrespective of their body weight and
adiposity.
Consistent with previous reports (Levi et al., 2011; Solomon
et al., 2014), blockade of LEPR signaling in lean, WT mice re-
sulted in significant hyperphagia and BW gain. The lack of effect
of PLA to regulate energy balance in LEPR-deficient db/dbmice
supports the specificity of PLA for the LEPR and a lack of ‘‘off-
target’’ effects in vivo. The dose of PLA given to db/db mice
was less than the maximally effective dose given to DIO animals
but was sufficient to induce changes in the BW of high-fat-fed
mice. PLA also failed to increase food intake in ob/ob mice,
but it did attenuate their BW gain, suggesting modest LEPR ag-
onism of the compound in this strain, described as having
increased leptin sensitivity (Harris et al., 1998).
A key neural circuit involved in the control of energy balance by
leptin is themelanocortin system, including direct and/or indirect
control of MC4R-expressing neurons by leptin (Ghamari-Lan-
groudi et al., 2011). Mc4r/ mice develop late-onset obesity
(Huszar et al., 1997), with hyperleptinemia and resistance to
the effect of exogenous administration of leptin (Marsh et al.,
1999). The failure of PLA/LA to induce hyperphagia in obese
Mc4r/mice supports a prominent role of themelanocortin sys-
tem to convey the anorectic action of endogenous leptin in adult
mice. This dramatic reduction of leptin action in obese, adult
Mc4r/ mice stands in contrast to the maintenance of leptin
sensitivity found in young, non-obese mice with Mc4r deletion
(Marsh et al., 1999) and with the effectiveness of PLA increasing
body weight and energy intake in young Mc4r/ mice. This
discrepancy suggests an age-dependent convergence from
multiple neural circuits toward the melanocortin system as the
mediator of leptin effects on the homeostatic control of energy
balance. Although this hypothesis remains to be corroborated
experimentally, it is supported by considerable evidence sug-
gesting age-dependent changes in leptin action (Gabriely
et al., 2002; Morrison et al., 2007; Newton et al., 2013; Scarpace
et al., 2000).
The reduced impact of subtracting endogenous leptin action
in mouse models of obesity caused by direct (i.e., db/db or882, June 2, 2015 ª2015 Elsevier Inc. 879
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Figure 3. Peripheral Administration of PLA or Central Infusion of LA
in Lean and DIO Mice
(A–L) Cumulative energy intake (A, D, G, and J), BW (B, E, H, and K), and BW
change (C, F, I, and L) of lean and DIO mice receiving either peripheral PLA
(1, 3, 10 nmol/kg/day i.p.) (A–I) or central infusion of LA (8 mg/day, i.c.v.) (J–L).
(M and N) Change in caloric intake (M) and BW (N) after 6 days of treatment
with either peripheral PLA or central LA.
Data are shown as mean ± SEM n = 7–8 (A–I) or n = 5 (J–L). *p < 0.05 Lean Veh
versus Lean PLA; #p < 0.05 DIO Veh versus DIO PLA. Two-way RM ANOVA
followed by Sidak test (A–L) or Student’s t test (M).
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Figure 4. Pomc and Socs3 Gene Expression and pSTAT3 Levels
in the Arcuate Nucleus of Mice Treated with Leptin Receptor
Antagonist
(A and B) Pomc (A) and Socs3 (B) expression after a single injection of PLA
(3 mg/kg i.p.) in DIO mice 1 hr before the onset of the dark phase.
(C and D) Pomc (C) and Socs3 (D) expression after 7 day treatment with PLA
(3 mg/kg i.p. once daily) on lean and DIO mice.
(E and F) pSTAT3 levels relative to beta actin (E) and to total STAT3 (F)
measured by immunoblot in ARC of lean or DIO mice after 7 day infusion with
i.c.v. LA (8 mg/day).
Data are shown as mean ± SEM; n = 5–7; *p < 0.05. Student’s t test (B); two-
way ANOVA followed by Sidak test (C–E).ob/ob mice) or indirect (Mc4r/ mice) disruption of leptin
signaling provides a striking contrast with the comparable induc-
tion of positive energy balance in DIO and age-matched lean
mice following the peripheral administration of PLA or central
infusion of LA. These findings show that DIOmicemaintain intact
endogenous leptin action despite hyperleptinemia and support
previous observations of the susceptibility of DIO rats to weight
gain when given the less-potent leptin receptor antagonist
(L39A/D40A/F41A) via i.c.v. (Tu¨mer et al., 2007). In addition to
hyperleptinemia, DIO mice exhibit reduced responses to exoge-
nously administered leptin, which has been linked to impair-
ments of the intracellular signaling cascade induced by the
activated LEPR (Coppari and Bjørbæk, 2012; Myers et al.,880 Cell Metabolism 21, 877–882, June 2, 2015 ª2015 Elsevier Inc.2008). One proposed mechanism of leptin resistance involves
reduced LEPR signaling as a result of increased Socs3 levels
(Bjørbaek et al., 1998). Increased Socs3 prevents the phosphor-
ylation of STAT3 by activated LEPR, providing a means of nega-
tive feedback regulation of leptin action in target cells (Myers
et al., 2008). Consistent with this view, hyperleptinemic, leptin-
resistant DIO mice exhibit increased baseline Socs3 expression
in the ARC (Enriori et al., 2007; Mu¨nzberg et al., 2004). Yet,
similar to previous studies using DIO mice (Knight et al., 2010;
Martin et al., 2006), we observed elevated basal pSTAT3 levels
in DIO mice compared to lean controls and a significant
decrease with PLA treatment. Since leptin receptor antagonism
reduced Socs3 gene expression, pSTAT3 levels, and the
expression of a target gene, Pomc (Mu¨nzberg et al., 2003), our
data are consistent with the hypothesis that increased Socs3
and pSTAT3 levels in the ARC of DIO mice are the direct conse-
quence of ongoing endogenous leptin signaling in these obese
animals. More importantly, this occurred at doses of antagonist
sufficient to elicit similar changes in energy intake and BW in lean
and DIO mice. Thus, although the increase in baseline Socs3
levels exhibited by DIO mice may attenuate the effect of exoge-
nously administered leptin, explaining the lack of expected hy-
pophagia or activation of LEPR signaling cascade, our results
suggest that DIO mice do not experience reduced endogenous
leptin action and in fact demonstrate that it plays a critical role
preventing further BW gain.
Our results suggest that DIO develops despite the sustained
contribution of endogenous leptin to regulate energy balance.
Thus, mechanisms opposing leptin must play a crucial role in
the development or maintenance of obesity. There is evidence
that some of these mechanisms may actually be LEPR depen-
dent, as suggested by the fact that mice overexpressing LEPR
in POMC neurons are more susceptible to DIO (Gamber et al.,
2012). On the other hand, transgenic mice exhibiting supraphy-
siological serum leptin levels remain leaner than WT controls
on a standard low-fat diet and reach the same BW when made
DIO, suggesting that hyperleptinemia alone is not sufficient to
reduce endogenous leptin action and cause obesity (Tanaka
et al., 2005). Conversely, ob/ob mice supplemented with suffi-
cient leptin to prevent obesity while fed a low-fat diet experience
similar BW gain compared to WT hyperleptinemic controls once
challenged with a HFD, despite remaining responsive to the
exogenous administration of leptin (Knight et al., 2010).
Assuming the limitations due to the intrinsic differences in leptin
action between ob/ob mice and WT mice (Bouret et al., 2004),
these data suggest that factors other than leptin have a relevant
role in the control of BW in conditions of energy surplus. Identi-
fying the factors involved in counteracting the effect of leptin dur-
ing the development of obesity may provide efficacious targets
to prevent BW gain.
The comparable effects of PLA/LA in WT lean and DIO mice
suggest that although hyperleptinemic mice may have close to
maximal LEPR activity, suppression of steady-state food intake
by endogenous leptin remains intact, contributing to the control
of energy balance. In our studies, this effect is comparable to that
of the lean control mice. This suggestion that our DIO mice have
near-maximal endogenous leptin action provides a caveat to the
therapeutic application of leptin to treat obesity. The relatively
modest effect of leptin to reduce body weight in obese humans
may be due to the limited benefit of increasing leptin levels in
already hyperleptinemic subjects (Heymsfield et al., 1999). In
contrast, use of leptin during BW loss, when leptin levels drop
and there is room for further LEPR activation, seems to be a
much more effective approach (Clemmensen et al., 2014; Mu¨ller
et al., 2012; Roth et al., 2008).
Overall, the findings presented here demonstrate comparable
endogenous leptin activity in lean and obese hyperleptinemic
diet-induced obese mice, despite different sensitivity to exoge-
nously administered leptin. These findings challenge the general
assumption of reduced leptin action in obesity, and they should
be considered in the development of therapies targeting leptin
signaling for the treatment of metabolic disease.CEXPERIMENTAL PROCEDURES
These studies were approved by the Institutional Animal Care and Use Com-
mittees at the University of Cincinnati Office in accordance with the US NIH
Guide for the Care and Use of Laboratory Animals.
Mice
All mice (C57/Bl6J, Lepob/ob, Leprdb/db, and LoxTbMc4r) were purchased from
The Jackson Laboratory and were acclimated for at least 1 week before the
study. Mice were single housed during the study and placed in a 12 hr light/
12 hr dark cycle at 22C with free access to food and water (see also Supple-
mental Experimental Procedures).
Leptin Antagonists
Native (LA) and 20K-PEGylated (PLA) mouse PLA (mutant D23L/L39A/D40A/
F41A) were synthetized and characterized as previously described (Shpilman
et al., 2011)
Intraperitoneal Injections
PLA was dissolved in PBS and administered intraperitoneally over a period of
6 days at doses of 1, 3, or 10 mg/kg daily in independent sets of mice. BW and
energy intake were monitored daily.
Intracerebroventricular Infusions
Mice received a cannula in the lateral cerebral ventricle connected to a
subcutanenous osmotic mini-pump (1007D; Alzet) filled with vehicle (PBS) or
LA infused at 8 mg/day for 7 days (see also Supplemental Experimental
Procedures).
Gene Expression Analysis
Pomc and Socs3 gene expression in the arcuate nucleus were analyzed using
commercially available gene-specific Taqman probes following manufacturer
instructions (see also Supplemental Experimental Procedures) and quantified
as described elsewhere (Muller et al., 2002).
Immunoblot
Levels of total STAT3 and pSTAT3 protein in the arcuate nucleus were de-
tected by immunoblot using commercially available antibodies, revealed using
chemiluminescense, and quantified using standard imaging techinques (see
also Supplemental Experimental Procedures).
Leptin Measurements
Leptin was measured using a commercially available ELISA from Alpco.
Statistical Analyses
Data are presented as mean ± SEM. Analyses were performed using
GraphPad Prism, version 6 (GraphPad Software). t tests were used for
comparison of two groups, and two-way ANOVA with or without repeated-
measures and Sidak multiple comparison tests were used for post hoc com-
parisons. p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.cmet.2015.04.015.
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